



Press Release

Bachem and Debio conclude long-term supply agreement for triptorelin pamoate

Bubendorf, Switzerland, March 16, 2006 - Bachem AG today announced the conclusion of a long-term agreement with Debio, a Swiss drug development company, for the supply of triptorelin pamoate. Under the terms of this agreement, Bachem will supply Debio with the active substance for its product Decapeptyl® (Trelstar® in the USA). Triptorelin pamoate is a peptidic active pharmaceutical ingredient (API), which is used for treating prostate cancer, endometriosis and premature puberty.

Walter Isler, Head of Marketing and Sales with Bachem AG, commented that Bachem "has already been working with Debio for a long time. We are very pleased that we have now been chosen as partner for a long-term supply agreement based on the reliability we have shown over the years".

Decapeptyl® was developed by Debio and has been marketed in Europe since 1986. This is a special injectable formulation of triptorelin pamoate with a controlled release action. Bachem has been supplying the peptidic API regularly for over 10 years on an individual order basis. The agreement that has now been concluded provides for the supply of guaranteed quantities at fixed conditions, which in turn guarantee Bachem budgetable sales over a period of several years. The delivery quantities are defined on the basis of detailed planning models and are supplied by Bachem through a call order.

About Bachem

Bachem is an independent, technology-based company specializing in the production of innovative biochemical for research purposes and pharmaceutical compounds for pharma and biotech industries as well as in the development of optimized manufacturing processes. With headquarters in Switzerland and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in its field.

For further question, please contact:

Bachem Holding AG
Michael Hüsler, CFO
Tel. +41 61 935 2333
Fax +41 61 935 2324
www.bachem.com